Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial

PURPOSE: To assess the efficacy, safety, and quality-of-life impact of switching adjuvant treatment in hormone receptor-positive primary breast cancer patients who are still premenopausal after 2–3 years of tamoxifen therapy to anastrozole plus goserelin as compared with continuing tamoxifen over a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian-wei, Liu, Guang-yu, Ji, Ya-jie, Yan, Xia, Pang, Da, Jiang, Ze-fei, Chen, De-dian, Zhang, Bin, Xu, Bing-he, Shao, Zhi-ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312049/
https://www.ncbi.nlm.nih.gov/pubmed/30643455
http://dx.doi.org/10.2147/CMAR.S183672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312049/
https://www.ncbi.nlm.nih.gov/pubmed/30643455
http://dx.doi.org/10.2147/CMAR.S183672

Ejemplares similares